Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals, Ltd.) on October 22, 2018, for the month of October 2018. The filing incorporates by reference a press release dated October 22, 2018, announcing a major technological breakthrough regarding the industrialization of the company's Apotainer™ stem cell product line.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a technological development announcement rather than financial performance data.
Material Changes
The material change reported is a significant technological advancement in the industrialization process of the Apotainer™ stem cell product line. No financial comparisons to prior periods are included in this document.
Outlook and Management Commentary
Management highlights a "major technological breakthrough" for the Apotainer™ product line. The filing incorporates "Forward Looking Statements" from the attached press release into the company's Registration Statements on Form S-8 and Form F-3. Specific details regarding future guidance, risks, or contingencies beyond the general nature of forward-looking statements are not detailed in the provided text.
Key Facts for Investor Verification
- Verify the specific technical details and commercial implications of the Apotainer™ industrialization breakthrough in the full press release (Exhibit 99.1).
- Confirm the company name is Cellect Biotechnology Ltd., as the metadata reference to Quoin Pharmaceuticals appears to be incorrect.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for the full text of the Forward Looking Statements.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F for financial metrics.